ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
193.02
0.00
(0.00%)
Closed June 18 4:00PM
0.00
0.00
(0.00%)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

AGN News

Official News Only

AGN Discussion

View Posts
ShadowVolcano37 ShadowVolcano37 3 weeks ago
back in the day (2020) it was a promising company. no wonder it has been purchased by AbbVie. despite the allergy related name, they invented Botox!
👍️0
barnyarddog barnyarddog 3 years ago
193.00 Game-Changer: The FDA Approved Eye Drops That Replace Reading Glasses

The drops, known as pilocarpine, and sold by pharma outlet Allergan under the name “Vuity,” might help the 128 million people in the United States who are nearsighted.

One drop in each eye, according to the business, may enhance closeup eyesight for six to ten hours, according to CBS News.

https://www.zerohedge.com/medical/game-changer-fda-approved-eye-drops-replace-reading-glasses
👍️0
JustJack JustJack 3 years ago
Please don’t invest your grandkids money here.
👍️0
JustJack JustJack 3 years ago
It doesn't look to be trading?

Did you do any DD you can pass along?

anyone looking to buy today?
👍️0
JustJack JustJack 3 years ago
What happened here rcookr1?
👍️0
DewDiligence DewDiligence 4 years ago
That's a wrap!
👍️0
DewDiligence DewDiligence 4 years ago
ABBV completes $65B AGN acquisition:

https://www.allergan.com/News/Details/2020/05/AbbVie%20Inc%20Completes%20Acquisition%20of%20Allergan%20plc

The deal, announced in Jun 2019 (#msg-149577810), entitles each AGN share to receive 0.886 shares of ABBV plus $120.30 in cash, a nominal value of $194.69/sh (3% higher than the nominal value of $188.24/sh nominal value at the time of the deal announcement).
👍️0
DewDiligence DewDiligence 4 years ago
1Q20 worldwide Botox sales=$812.2M, -6% YoY, -20% QoQ*:

https://www.sec.gov/ix?doc=/Archives/edgar/data/1578845/000156459020022386/agn-10q_20200331.htm

• US therapeutic: $395.8M (-1% YoY, -15% QoQ*)
• US cosmetic: $212.7M (-7% YoY, -22% QoQ*)
--
US total: $608.5M (65% therapeutic; 35% cosmetic) was 75% of worldwide total


• Ex-US therapeutic: $89.3M (-1% YoY, -13% QoQ*)
• Ex-US cosmetic: $114.4M (-21% YoY, -37% QoQ*)
--
Ex-US total: $203.7M (44% therapeutic; 56% cosmetic) was 25% of worldwide total


*Apart from the COVID-19 pandemic, Botox sales are seasonally stronger in the second and fourth calendar quarters than in the first and third quarters.
👍️0
DewDiligence DewDiligence 4 years ago
ABBV-AGN merger expected to close 5/8/20:

https://finance.yahoo.com/news/announcement-relating-outcome-court-sanction-105500126.html
👍️0
DewDiligence DewDiligence 4 years ago
Following FTC agreement, ABBV-AGN plan May 2020 merger closing:

https://www.prnewswire.com/news-releases/abbvie-and-allergan-sign-consent-decree-agreement-with-federal-trade-commission-staff-on-pending-transaction-301025767.html
👍️0
DewDiligence DewDiligence 4 years ago
ABBV-AGN receive EU approval for merger—US FTC approval still pending:

https://finance.yahoo.com/news/abbvie-allergan-receive-final-european-130000384.html
👍️0
DewDiligence DewDiligence 4 years ago
4Q19 worldwide Botox sales=$1.020B, +8% YoY, +10% QoQ*:

https://allergan.gcs-web.com/node/22536/pdf

• US therapeutic: $463.0M (+7% YoY, +7% QoQ*)
• US cosmetic: $271.8M (+6% YoY, +14% QoQ*)
--
US total: $734.8M (63% therapeutic; 37% cosmetic) was 72% of worldwide total


• Ex-US therapeutic: $102.5M (+9% YoY, +9% QoQ*)
• Ex-US cosmetic: $182.9M (+20% YoY, +10% QoQ*)
--
Ex-US total: $285.4M (36% therapeutic; 64% cosmetic) was 28% of worldwide total


*Botox sales are seasonally stronger in the second and fourth calendar quarters than in the first and third quarters.
👍️0
DewDiligence DewDiligence 4 years ago
FDA approves AGN’s Ubrelvy (ubrogepant) for acute migraine treatment:

https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-adults-migraine

Ubrelvy may do well in the crowded CGRP arena because it’s oral.

AGN has a second oral CGRP candidate, Atogepant, in development for migraine prevention.

AGN acquired both drugs from MRK in 2015 for what now appears to be a very reasonable price (#msg-115206907).
👍️0
DewDiligence DewDiligence 5 years ago
3Q19 worldwide Botox sales=$928.7M, +6% YoY, -5% QoQ*:

https://www.allergan.com/News/Details/2019/11/Allergan%20Reports%20Third%20Quarter%202019%20Financial%20Results

• US therapeutic: $431.6M (+6% YoY, -3% QoQ*)
• US cosmetic: $237.6M (+10% YoY, -6% QoQ*)
--
US total: $669.2M (64% therapeutic; 36% cosmetic) was 72% of worldwide total


• Ex-US therapeutic: $93.9M (+5% YoY [constant currency], -5% QoQ*)
• Ex-US cosmetic: $165.6M (+6% YoY [constant currency], -6% QoQ*)
--
Ex-US total: $259.5M (36% therapeutic; 64% cosmetic) was 28% of worldwide total


*Botox sales are seasonally stronger in the second and fourth calendar quarters than in the first and third quarters.
👍️0
DewDiligence DewDiligence 5 years ago
2Q19 worldwide Botox sales=$974.0M, +4% YoY, +12% QoQ*:

https://www.allergan.com/News/News/Thomson-Reuters/Allergan-Reports-Second-Quarter-2019-Financial-Res

• US therapeutic: $447.0M (+6% YoY, +12% QoQ)
• US cosmetic: $252.4M (+7% YoY, +10% QoQ)
--
US total: $699.4M (64% therapeutic; 36% cosmetic)


• Ex-US therapeutic: $98.8M (+1% YoY [constant currency], +5% QoQ)
• Ex-US cosmetic: $175.8M (+11% YoY [constant currency], +19% QoQ)
--
Ex-US total: $274.6M (36% therapeutic; 64% cosmetic)


*Botox sales are seasonally stronger in the second and fourth calendar quarters than in the first and third quarters.
👍️0
jdlamont jdlamont 5 years ago
agn looking to buy EYEN. still a no brainer
👍️0
DewDiligence DewDiligence 5 years ago
LOL. These lawsuit PRs are pre-written fill-in-the-blanks forms ready to go at any moment.
👍️0
whytestocks whytestocks 5 years ago
News: $AGN Allergan Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Allergan plc is Fair to Shareholders - AGN

NEW YORK, June 25, 2019 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Allergan plc (NYSE: AGN) to AbbVie Inc. (“AbbVie”) is fair to Allergan shareholders. On behalf of Allergan shareholders, Halper Sadeh LLP may s...

Find out more https://marketwirenews.com/news-releases/allergan-merger-investigation-halper-sadeh-llp-announces-investigation-into-whether-the-sale-of-allergan-plc-is-fair-to-shareholders-agn-8411800.html
👍️0
DewDiligence DewDiligence 5 years ago
ABBV-AGN CC slides:

https://investors.abbvie.com/static-files/7b4c052f-bf32-4917-a239-0c1c9416550a
👍️0
whytestocks whytestocks 5 years ago
News: $AGN AbbVie to Acquire Allergan in Transformative Move for Both Companies

NORTH CHICAGO , Ill. and DUBLIN , June 25, 2019 /PRNewswire/ -- AbbVie Inc. (NYSE: ABBV) and Allergan plc (NYSE: AGN)  announced that the companies have entered into a definitive transaction agreement under which AbbVie will acquire Allergan in a cash and stock transaction...

In case you are interested https://marketwirenews.com/news-releases/abbvie-to-acquire-allergan-in-transformative-move-for-both-companies-8409708.html
👍️0
DewDiligence DewDiligence 5 years ago
RF-frequency devices for aesthetic applications go back at least 15 years to a company called Thermage (#msg-3876193). The THRM device never sold well and ended up being a swanky coat hanger at many doctor’s offices (#msg-11593419, #msg-29182011). THRM, which became SLTM, was eventually bought by Valeant Pharmaceuticals (the ultimate roll-up company) in 2013.

THRM’s device used RF-frequency waves to heat cells. I’m unclear how RF can used to cool cells, as AGN’s CoolTone supposedly does.
👍️0
semi_infinite semi_infinite 5 years ago
The Zeltiq device is cryogenic and seems to work according to a couple of relatives that have tried it. The cool tone device is magnetic and not as proprietary. There are already devices on the market such as the one below. I would like to see the data supporting the claim that 1.35T gives better results than 0.9T.

https://www.venusconcept.com/en-us/venus-freeze-plus.htm

https://www.venusconcept.com/en-us/venus-legacy.htm
👍️0
RichardSawars RichardSawars 5 years ago
~ 60% more effective then laser removal. Shorter treatments (2 months average vs ~ 1 year avg removal) without inflicting pain on clients.

Do some more Dewdiligence on it.
👍️0
DewDiligence DewDiligence 5 years ago
[OT]—I would question the business plan of any company that’s working on cellulite.

What’s differentiating about SOLY as compared to tattoo removal by laser?
👍️0
RichardSawars RichardSawars 5 years ago
In regards to AGN.. Has anyone heard of SOLY yet? The board of the company was recently involved with a similar company that developed a breakthrough fat reduction therapy that was purchased by AGN for 56$ ps or 2.4B.

$SOLY has patented technology on industry leading tattoo removal (RAP) & they announce their trial results for cellulite removal today.
👍️0
DewDiligence DewDiligence 5 years ago
AGN 1Q19 CC transcript:

https://finance.yahoo.com/news/edited-transcript-agn-earnings-conference-123003495.html
👍️0
DewDiligence DewDiligence 5 years ago
AGN 1Q19 CC slides:

http://phx.corporate-ir.net/External.File?t=1&item=VHlwZT0yfFBhcmVudElEPTUyNzg1NzN8Q2hpbGRJRD03MDY1MjY=
👍️0
DewDiligence DewDiligence 5 years ago
(From AGN’s PR)—1Q19 worldwide Botox sales=$868.4M, +6% YoY (-8% QoQ*):

• US therapeutic: $397.6M (+6 YoY, -8% QoQ*)
• US cosmetic: $229.5M (+17% YoY, -11% QoQ*)
--
Total US sales: $627.1M (63% therapeutic, 37% cosmetic)


• Ex-US therapeutic: $93.9 (+7% YoY, -3% QoQ*)
• Ex-US cosmetic: $147.4M (+9% YoY, -7% QoQ*)
--
Total ex-US sales = $241.3M (39% therapeutic, 61% cosmetic)


*The 1Q19 QoQ decline relative to 4Q18 was expected; Botox is seasonally stronger in the second and fourth quarters of the calendar year.
👍️0
DewDiligence DewDiligence 5 years ago
AGN 1Q19 results:

https://www.allergan.com/News/News/Thomson-Reuters/Allergan-Reports-First-Quarter-2019-Financial-Resu
👍️0
DewDiligence DewDiligence 5 years ago
Abicipar pegol (a/k/a DARPin) shows 8.9% ocular inflammation in open-label study with new manufacturing process—lower than the 15% rate in prior phase-3 trials, but still too high to be competitive (IMO):

https://finance.yahoo.com/news/allergan-molecular-partners-announce-topline-110000485.html

AGN, by its own admission, was aiming for an inflammation rate in the low-to-mid single digits.
👍️0
DewDiligence DewDiligence 5 years ago
Three phase-3 Rapastinel trials stopped for futility:

https://www.prnewswire.com/news-releases/allergan-announces-phase-3-results-for-rapastinel-as-an-adjunctive-treatment-of-major-depressive-disorder-mdd-300808044.html
👍️0
DewDiligence DewDiligence 5 years ago
AGN 4Q18 CC transcript:

https://finance.yahoo.com/news/edited-transcript-agn-earnings-conference-213849663.html
👍️0
DewDiligence DewDiligence 5 years ago
AGN 4Q18 CC slides:

https://www.allergan.com/news/assets/q4-2018-earnings-deck_final
👍️0
DewDiligence DewDiligence 5 years ago
AGN 4Q18 results:

http://phx.corporate-ir.net/External.File?t=1&item=VHlwZT0yfFBhcmVudElEPTUyNzcwMDh8Q2hpbGRJRD03MDM1MTE=
👍️0
whytestocks whytestocks 5 years ago
News: $AGN CoolSculpting® and Sonja Morgan Partner To Get Real About Self-Care

DUBLIN , Jan. 15, 2019 /PRNewswire/ -- Television personality on Bravo's "The Real Housewives of New York City ", philanthropist, fashion lifestyle entrepreneur and mom, Sonja Morgan , is partnering with CoolSculpting, owned by Allergan plc (NYSE: AGN), as the face of the brand's l...

Read the whole news https://marketwirenews.com/news-releases/coolsculpting-xae-and-sonja-morgan-partner-to-get-real-about-self-care-6831048.html
👍️0
DewDiligence DewDiligence 5 years ago
AGN -7% on permanent recall of “textured” breast implants in Europe:

https://finance.yahoo.com/news/allergan-suspends-sales-withdraws-supply-133000863.html
👍️0
DewDiligence DewDiligence 6 years ago
AGN 3Q18 CC transcript:

https://finance.yahoo.com/news/allergan-plc-agn-q3-2018-164449472.html
👍️0
DewDiligence DewDiligence 6 years ago
Reason for today’s selloff: #msg-144555471.
👍️0
DewDiligence DewDiligence 6 years ago
AGN 3Q18 results items…

PR:
http://phx.corporate-ir.net/External.File?t=1&item=VHlwZT0yfFBhcmVudElEPTUyNzU1Mjd8Q2hpbGRJRD03MDEwNzI=

CC slides:
https://www.allergan.com/news/assets/final-deck-q3-2018-10-30-2018.aspx
👍️0
DewDiligence DewDiligence 6 years ago
AGN slides from AAO webcast:

http://phx.corporate-ir.net/External.File?t=1&item=VHlwZT0yfFBhcmVudElEPTUyNzU4MTF8Q2hpbGRJRD03MDA5ODI=
👍️0
DewDiligence DewDiligence 6 years ago
AGN slides from Medical Aesthetics Day:

http://phx.corporate-ir.net/External.File?t=1&item=VHlwZT0yfFBhcmVudElEPTUyNzQ0Nzh8Q2hpbGRJRD02OTk5MDQ=
👍️0
DewDiligence DewDiligence 6 years ago
Re: AGN's internal long-acting toxin

#msg-143560931
#msg-143560695
👍️0
DewDiligence DewDiligence 6 years ago
AGN acquires (private) Bonti for $195M plus contingencies:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143556549

Bonti’s product candidate is a type-E botulinum toxin, which is an altogether different animal from type-A botulinum toxins such as Botox and RVNC’s RT002.

I previously commented on Bonti in #msg-137948777 and #msg-137955390.
👍️0
DewDiligence DewDiligence 6 years ago
AGN receives CRL for Ulipristal treatment for uterine fibroids:

https://www.prnewswire.com/news-releases/allergan-receives-complete-response-letter-from-the-us-food-and-drug-administration-for-ulipristal-acetate-new-drug-application-300700400.html
👍️0
DewDiligence DewDiligence 6 years ago
AGN, EDIT announce mutual opt-ins on EDIT-101: #msg-142720697.
👍️0
DewDiligence DewDiligence 6 years ago
More granularity of 2Q18 Botox sales: #msg-142479825.
👍️0
DewDiligence DewDiligence 6 years ago
Transcript of AGN 2Q18 CC:

https://finance.yahoo.com/news/edited-transcript-agn-earnings-conference-213321827.html
👍️0
DewDiligence DewDiligence 6 years ago
AGN 2Q18 items…

PR:
https://finance.yahoo.com/news/allergan-reports-strong-second-quarter-103000561.html

CC slides:
http://www.allergan.com/news/assets/q2-2018-earnings-presentation.pdf
👍️0
DewDiligence DewDiligence 6 years ago
AGN/MOLN.SW report phase-3 AMD data for Abicipar (a/k/a DARPin):

#msg-142311304
👍️0
DewDiligence DewDiligence 6 years ago
AGN 1Q18 CC transcript:

https://finance.yahoo.com/news/edited-transcript-agn-earnings-conference-224140279.html
👍️0

Your Recent History

Delayed Upgrade Clock